Lightnews — Scholar-powered news

Reposted by Prof Joseph F Hayes

Tom Metherell @tommetherell.com · Jul 14

We have a ✨NEW PREPRINT✨! Using data from the @clscohorts.bsky.social Millennium Cohort Study and linked healthcare records, we tested the association between social media use and psychiatric diagnoses in secondary care in young people in England. This is still a work in progress - feedback welcome!

PsyArXivBot @psyarxivbot.bsky.social · Jul 8

Characterising the longitudinal relationship between social media use and psychiatric diagnoses in secondary care in adolescents in England: https://osf.io/87cze

3 11 24

Prof Joseph F Hayes @jfhayes.bsky.social · Jul 9

This is not to say no one experiences symptoms on discontinuation of antidepressants, but trial data don’t show us this and they are the best method we have to find a causal association between antidepressants cessation and symptoms.

1 1

Prof Joseph F Hayes @jfhayes.bsky.social · Jul 9

Why would researchers want to inflate the problem? It’s probably both ideological and financial www.wired.com/story/taperi...

‘Uber for Getting Off Antidepressants’ Launches in the US

Outro, which is now available in seven states, wants to help people taper off antidepressants without experiencing debilitating side effects.

www.wired.com

1 1 3

Prof Joseph F Hayes @jfhayes.bsky.social · Jul 9

Certainly from trials we see there is a unique profile of discontinuation symptoms, but the clinical impact is far less than some researchers would have you believe.

1 1

Prof Joseph F Hayes @jfhayes.bsky.social · Jul 9

Since Davies & Read review of 2019 Sameer Jauhar and I have been trying to get closer to the truth about AD discontinuation. It’s entered guidelines as FACT: 50% will experience difficulty stopping. So we completed the DEFINITITIVE meta-analysis of trial data.

jamanetwork.com/journals/jam...

Incidence and Nature of Antidepressant Discontinuation Symptoms

This systematic review and meta-analysis examines the presence and incidence of discontinuation symptoms in individuals who stop taking antidepressants.

jamanetwork.com

2 3 4

Prof Joseph F Hayes @jfhayes.bsky.social · May 9

The association between gabapentinoids and risk of self-harm is multifaceted: These findings do not support a direct effect of gabapentinoid treatment on self-harm but underscore the necessity for close patient monitoring throughout the gabapentinoid treatment journey www.bmj.com/content/389/...

Use of gabapentinoid treatment and the risk of self-harm: population based self-controlled case series study

Objective To estimate the effect of gabapentinoid treatment on self-harm. Design A population based self-controlled case series study. Setting UK Clinical Practice Research Datalink Aurum data...

www.bmj.com

1

Prof Joseph F Hayes @jfhayes.bsky.social · May 9

Thanks for your interest in our study. I agree with your summary and the issues raised.

Department of Psychiatry, University of Oxford @oxfordpsychiatry.bsky.social · May 6

NEW EDITORIAL 📢
Seena Fazel and Amir Sariaslan respond to a paper looking at the risk of self-harm in people prescribed gabapentinoids (gabapentin and pregabalin) - a class of drugs which are often used to treat epilepsy and pain disorders Read it in the BMJ: www.bmj.com/content/389/...

Use of real world data to understand self-harm risk in people prescribed gabapentinoids

Consider routine follow-up, especially after medication has been stopped Gabapentinoids, including gabapentin and pregabalin, are a class of drugs that have anticonvulsant, analgesic, and anxiolytic ...

www.bmj.com

2

Prof Joseph F Hayes @jfhayes.bsky.social · Apr 6

Metformin is recommended for antipsychotic associated weight gain. However, in >25k patients initiating antipsychotics, only 3.3% received metformin in the first 2 years. In this small group, it seems to work: patients lost 0.65% of their body weight vs. gaining 4.16% on antipsychotics alone.

Co-prescription of metformin and antipsychotics in severe mental illness: a UK primary care cohort study

Background Metformin is a pharmacological candidate to mitigate second-generation antipsychotic (SGA)-induced weight gain in patients diagnosed with severe mental illnesses (SMI).Objective To determin...

mentalhealth.bmj.com

1 1 2

Prof Joseph F Hayes @jfhayes.bsky.social · Mar 5

What about the lack of spell checker for comments? Shows me how much of my typing is just mashing the keyboard.

1

Prof Joseph F Hayes @jfhayes.bsky.social · Feb 26

FDA removes risk evaluation and mitigation for clozapine, including neutrophil monitoring www.fda.gov/drugs/postma...

Information on Clozapine

www.fda.gov

2 2 1

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 27

This target trial emulation study of >25k patients finds no difference in total cholesterol at one year, but lower BMI and BP. And no difference in psychiatric hospital admission rates journals.plos.org/plosmedicine...

Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation

In a target trial emulation, Alvin Richards-Belle and colleagues compare the efficacy and safety profile of aripiprazole and other second-generation antipsychotics in patients diagnosed with severe me...

journals.plos.org

2

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 27

It’s generally agreed that aripiprazole conveys less cardiometabolic risk than the other, commonly prescribed, second gen antipsychotics, but that it’s potentially less effective. But there is a lack of evidence for this position.

Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation

In a target trial emulation, Alvin Richards-Belle and colleagues compare the efficacy and safety profile of aripiprazole and other second-generation antipsychotics in patients diagnosed with severe me...

journals.plos.org

1 4

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 16

New #datamind paper: physical health screening in people with severe mental illness in the UK is insufficient. Until it improves, it seems hard to see how we will move the needle on premature mortality in this population

Prevalence and patient characteristics associated with cardiovascular disease risk factor screening in UK primary care for people with severe mental illness: an electronic healthcare record study

Background People with severe mental illness (SMI) are at increased risk of cardiovascular disease (CVD), and initiatives for CVD risk factor screening in the UK have not reduced disparities. Objecti...

mentalhealth.bmj.com

1 3

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 13

“Unease”

“This is really quite a good programme” Joanna Moncrieff on ‘Nazi Propagantist’ Tucker Carlson.

1 1 6

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 13

Unfortunately a nuanced story is far less compelling than pitching this as a simple “good vs evil”.

Tania Gergel @drtgergel.bsky.social · Jan 12

2/2 I suppose that rigorous rebuttals which demonstrate the flaws in a piece of research are just not considered interesting by @thetimes.com journalists.
rdcu.be/d50Xp
@sameerjauhar.bsky.social @jfhayes.bsky.social @profrobhoward.bsky.social @dranniehickox.bsky.social @carminepariante.bsky.social

A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression

Molecular Psychiatry - A recent “umbrella” review examined various biomarkers relating to the serotonin system, and concluded there was no consistent evidence implicating serotonin in...

rdcu.be

Prof Joseph F Hayes @jfhayes.bsky.social · Jan 3

New (expensive) drugs don’t gain QALYs www.thelancet.com/journals/lan...

Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis

During 2000–20, NHS coverage of new drugs displaced more population health than it generated. Our results highlight the inherent trade-offs between individuals who directly benefit from new drugs and those who forgo health due to the reallocation of resources towards new drugs.

www.thelancet.com

1 1 2

Prof Joseph F Hayes @jfhayes.bsky.social · Dec 18

Great work from @Alvin Richards-Belle et al.

2

Prof Joseph F Hayes @jfhayes.bsky.social · Dec 18

High dose prescribing is more likely for: people with schizophrenia, minoritized ethic groups, younger people, men and people from more deprived areas

1

Prof Joseph F Hayes @jfhayes.bsky.social · Dec 18

If bipolar then it’s quetiapine:

1

Prof Joseph F Hayes @jfhayes.bsky.social · Dec 18

The patterns differ by diagnosis. If you have a schizophrenia, you are most likely to get olanzapine:

1 1

Prof Joseph F Hayes @jfhayes.bsky.social · Dec 18

In the UK, 80% of antipsychotic prescribing is for one of 4 drugs: olanzapine, quetiapine, risperidone or aripiprazole

Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000–2019: 20-year investigation of who receives treatment, with which agents and at what doses | The B...

Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000–2019: 20-year investigation of who receives treatment, with which agents and at what doses

www.cambridge.org

1 7 13

Prof Joseph F Hayes @jfhayes.bsky.social · Nov 21

I stand by everything I've ever said on Twitter, so I've put it all here. Lets see how it fairs, shorn of any context. New material coming soon.

1 1

Prof Joseph F Hayes @jfhayes.bsky.social · Nov 16

Hi there! Yes please

1 1

Prof Joseph F Hayes @jfhayes.bsky.social · Nov 22

Is @altmetric a good enough reason to stay on X?

Prof Joseph F Hayes @jfhayes.bsky.social · Nov 22

Like data science and health informatics for mental health? Come and work with us: